Decline in ICD unit sales due to competition from MRI-compatible products
First written in FY2018-Q1. 7 of 17 entries say "Mitigated", first in FY2019-Q1. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025MitigatedAnnual report
「Meanwhile, sales of S-ICD, a core product, remained strong and revenue grew at a double-digit rate, helped by successful promotional initiatives including procedural training programs for physicians.」
Amid pressure on ICD-related sales from competing products, promotional initiatives for S-ICD drove double-digit growth in revenue from the product. - FY2025-H1MitigatedAnnual report
「Meanwhile, sales of S-ICD, a core product, remained strong as the number of new implant procedures increased substantially, and ICD-related revenue reached a record high on a half-year basis.」
Although pressure on ICD-related sales due to competing products had been reported, the increase in new S-ICD implant procedures brought ICD-related revenue to a half-year record high. - FY2024-Q3MitigatedAnnual report
「ICD-related revenue increased 11.0% year on year. Focused sales expansion initiatives for S-ICD, the only product of its kind in the market, increased the number of newly adopting facilities and improved the repeat rate. As a result, ICD-related revenue reached a record high on a quarterly basis.」
Although pressure on ICD sales from competing products had been reported, expansion of S-ICD sales increased the number of newly adopting facilities and improved the repeat rate, bringing ICD-related revenue to a quarterly record high. - FY2024-Q2MitigatedAnnual report
「ICD-related revenue increased 9.4% year on year, reaching a record high on a half-year basis. As S-ICD is the only product of its kind in the market, the company continued to focus on nationwide sales expansion initiatives as a strategic product.」
Although pressure on ICD-related sales due to competing products had previously been reported, ICD-related revenue increased 9.4% year on year, reaching a record high on a half-year basis, driven in part by nationwide expansion of S-ICD sales. - FY2023-Q3MitigatedAnnual report
「ICD-related revenue increased year on year, driven by a higher share in T-ICD from securing replacement cases as batteries reached the end of their service life, as well as strong CRT-D sales.」
Although ICD-related revenue declines due to the impact of competing products had previously been reported, ICD-related revenue increased year on year, supported by T-ICD share gains and strong CRT-D sales. - FY2022WorsenedAnnual report
「However, revenue from S-ICD and CRT-D declined from the previous fiscal year.」
In addition to the existing risk to ICD sales from competing products, S-ICD and CRT-D revenue declined year on year during the period. - FY2022-Q1WorsenedAnnual report
「In the ICD-related business for the treatment of tachycardia, the company's one-of-a-kind S-ICD product, EMBLEM MRI S-ICD, performed steadily. However, S-ICD leads were affected by the phased reimbursement price reductions in January and April 2021, while sales of conventional ICDs (implantable cardioverter-defibrillators) and CRT-Ds (biventricular pacemakers with defibrillation) declined year on year, partly due to the impact of competing products.」
While S-ICD remained firm, revenue from conventional ICDs and CRT-Ds declined due to the impact of competing products, and pressure on sales volumes and revenue from competition re-emerged. - FY2021-Q2MitigatedAnnual report
「In ICD-related products used to treat tachycardia, revenue increased as sales volumes of ICDs and CRT-Ds rose substantially compared with the period through August 2019, when products from the former business partner were handled.」
For ICD-related products, where declining sales volumes due to competitors' MRI-compatible products had previously been reported, sales volumes increased substantially after the change in business partner, resulting in higher revenue. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company disclosed that there was no material change in the risk of declining ICD sales volumes due to competitors' MRI-compatible products. - FY2020-Q2RestatedAnnual report
「No new business or other risks arose during the six-month period ended [the second quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there was no material change in the risk of declining ICD sales volumes due to competitors' MRI-compatible products. - FY2020-Q1RestatedAnnual report
「The product is highly regarded in clinical practice because it is expected to reduce lead-related complications, and sales volume has grown rapidly since the Company began handling it.」
Although S-ICD sales volumes grew rapidly and rhythm-management devices as a whole generated higher revenue, there is no disclosure of any new change in the underlying risk to conventional ICD sales from competitors' MRI-compatible products. - FY2019-Q2WorsenedAnnual report
「In ICD-related products, the company began selling PLATINIUM 4LV SonR CRT-D, a new CRT-D product, in July this year and is working to expand sales. However, ICD-related revenue declined from the same period of the previous year due to the impact of competitors' products compatible with MRI examinations.」
Although sales of the new PLATINIUM 4LV SonR CRT-D began, ICD-related revenue declined year on year due to the impact of competitors' MRI-compatible products. This marks a return to decline after remaining broadly at the level of the same period of the previous year in the preceding quarter. - FY2019-Q1MitigatedAnnual report
「ICD-related revenue remained broadly at the level of the same period of the previous year, as the impact of revisions to reimbursement prices was also limited.」
ICD-related revenue remained broadly at the level of the same period of the previous year, indicating a recovery from the declines in sales volumes and revenue previously reported. - FY2018RestatedAnnual report
「In ICD-related products, the company began selling PLATINIUM 4LV, a CRT-D compatible with quadripolar left-ventricular pacing leads, in July last year and is working to expand sales. However, total ICD-related revenue declined from the previous fiscal year due to the impact of competitors' MRI-compatible devices.」
Although the company is expanding sales of PLATINIUM 4LV, total ICD-related revenue has continued to decline due to competitors' MRI-compatible devices. - FY2018-Q3RestatedAnnual report
「In the PLATINIUM series, which is compact and characterized by a long service life, the company launched PLATINIUM 4LV, a CRT-D compatible with quadripolar left-ventricular pacing leads, in July last year and is working to expand sales. However, sales volumes declined from the same period of the previous year due to the impact of competitors' MRI-compatible products.」
Although the company is expanding sales of PLATINIUM 4LV, the decline in ICD sales volumes due to competitors' MRI-compatible products has continued. - FY2018-Q2RestatedAnnual report
「In the PLATINIUM series, which is compact and characterized by a long service life, the company began selling PLATINIUM 4LV, a CRT-D compatible with quadripolar left-ventricular pacing leads that expands the treatment options for pacing therapy, in July this year and is working to expand sales. However, sales volumes declined from the same period of the previous year due to the impact of competitors' MRI-compatible products.」
Although sales of PLATINIUM 4LV began, ICD sales volumes continued to decline due to the impact of competitors' MRI-compatible products. - FY2018-Q1First statedAnnual report
「In ICD-related products, although the company is working to expand sales of the compact, long-life PLATINIUM series, sales volumes declined from the same period of the previous year due to the impact of MRI-compatible products sold by competitors.」
Competitors' MRI-compatible products have translated into an actual year-on-year decline in ICD sales volumes.